RxCelerate
RxCelerate is a UK-based private CRO providing complete preclinical drug development programmes and proprietary proteomics services (ProQuant™) to virtual and semi-virtual biotechnology and pharmaceutical companies, headquartered in Babraham with 51-100 employees.
- Company typePrivate
- Founded2012
- HeadquartersBabraham, United Kingdom
- Headcount51–100
- GTM typeB2B
- OfferingServices
What RxCelerate does
RxCelerate is a UK-based private contract research organisation headquartered in Babraham, founded in 2012, providing complete preclinical drug development programmes and project management services to virtual and semi-virtual biotechnology and pharmaceutical companies. The company employs 51-100 staff and operates in the biotech and pharmaceutical R&D services market, with a stated focus on drug discovery and development for clients lacking full in-house infrastructure.
The company's core technical asset is the ProQuant™ proteomics platform, a proprietary offering launched in November 2022 concurrent with the acquisition of Methuselah Health UK Ltd. The platform is positioned to deliver high quantitative accuracy in proteomics for drug discovery and development applications, including support for biologic therapeutic candidate development. RxCelerate has supplemented this organic capability through a series of acquisitions: The Cambridge Partnership Ltd (2018), Prosarix (2019), and Methuselah Health UK Ltd (2022), building an integrated preclinical services portfolio.
The revenue model is not publicly disclosed. Customer segmentation is vertical, targeting Biotechnology Companies and Pharmaceutical Companies requiring advanced proteomics and preclinical drug development capabilities. In November 2025, RxCelerate entered a strategic co-development partnership with Constructive Bio to develop next-generation biologics, signalling a potential evolution from pure fee-for-service CRO work toward collaborative therapeutic development. Leadership is founder-led, with David Grainger as co-founder and executive chairman and Jill Reckless as co-founder and CEO.
RxCelerate firmographics
Firmographics- Name
- RxCelerate
- Website
- https://rxcelerate.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- RxCelerate is a UK-based private CRO providing complete preclinical drug development programmes and proprietary proteomics services (ProQuant™) to virtual and semi-virtual biotechnology and pharmaceutical companies, headquartered in Babraham with 51-100 employees.
- Ownership category
- akta.pro rank
RxCelerate industry classification
Industry- Product category
- Preclinical Drug Development Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Medical Laboratories (8071)
- akta.pro primary industry
- Proteomics & Biomarker Analytical Testing (HLAGADAG)
- akta.pro secondary industry
- Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)
Keywords
Where RxCelerate is headquartered
LocationHeadquarters
- HQ city
- Babraham
- HQ country
- United Kingdom
- HQ region
- Europe
Markets served
RxCelerate business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations
RxCelerate product offering
Product offeringCore offering
RxCelerate delivers complete preclinical drug development programmes and project management for virtual and semi-virtual biotechnology and pharmaceutical companies. Its offering is anchored by the proprietary ProQuant™ proteomics platform, which provides high quantitative accuracy proteomics services enabling advanced applications in drug discovery and development, including biologic therapeutic candidates developed in partnership with programmable biology platforms.
Product overview
RxCelerate operates as an R&D services provider in the biotech and pharmaceutical markets. The company's core product portfolio centers on the ProQuant™ proteomics platform, which was launched following the acquisition of Methuselah Health UK Ltd. The platform provides high quantitative accuracy proteomics services enabling advanced applications in drug discovery and development.
Differentiator
Problem solved
Functional benefit
Products and services
- ProQuant™ proteomics platform A proprietary proteomics platform acquired from Methuselah Health UK Ltd and launched by RxCelerate to provide high quantitative accuracy proteomics services for advanced applications in drug discovery and development, serving biotechnology and pharmaceutical clients.
- Preclinical Drug Development Programmes
Companies that use RxCelerate
Customer profileSegments2 records
Ideal customer profiles2 records
RxCelerate technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
RxCelerate partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Constructive BiocoreStrategic partnership to develop biologic therapeutic candidates using Constructive Bio's proprietary programmable biology platform. The collaboration aims to create next-generation biologics with enhanced properties for treating complex diseases. This represents a core co-development partnership combining RxCelerate's proteomics capabilities with Constructive Bio's programmable biology platform.
Scale indicators1 record
Recent moves5 records
Expansion highlights3 records
RxCelerate competitors and assessment
Company assessmentDirect peers
- Evotec: Global drug discovery and development CRO offering integrated services from target identification through preclinical work; directly comparable to RxCelerate's preclinical CRO and biologics co-development positioning, though at significantly greater scale.
- Sygnature Discovery: UK-based drug discovery CRO offering medicinal chemistry, in vitro biology, and DMPK services to virtual and semi-virtual biotechs; directly comparable in geography, customer base, and integrated preclinical program support model.
- Domainex: UK-based integrated drug discovery CRO providing services from target expression through candidate selection; closely comparable in service scope, geography, and reliance on biotech sponsors as primary customers.
- Concept Life Sciences: UK-based drug discovery CRO providing integrated discovery and development services; comparable in size, geography, and target customer profile of small-to-mid biotechs.
- Selvita: European CRO offering drug discovery, medicinal chemistry, and biology services to biotech and pharma clients; comparable service mix and customer segments, with proteomics-adjacent capabilities.
Broad incumbents
- Charles River Laboratories: Large, publicly-listed preclinical CRO providing discovery, safety assessment, and manufacturing services across pharma and biotech; serves the same customer segments as RxCelerate with much broader capabilities and global reach.
- Pharmaron: China-headquartered CRO/CDMO offering preclinical drug discovery and development services including biology and DMPK; comparable service mix with global scale advantages.
- WuXi AppTec: One of the largest global CRO/CDMOs with end-to-end discovery, preclinical, and clinical capabilities; serves the same biotech and pharma customers with much broader service breadth and geographic footprint.
- Eurofins Discovery: Division of Eurofins Scientific offering drug discovery services including in vitro biology, ADME, and proteomics-related offerings; broader portfolio play overlapping with RxCelerate's preclinical and proteomics service lines.
Emerging players
- Crown Bioscience: Preclinical CRO with translational biology and biomarker capabilities supporting drug discovery for oncology and other indications; comparable in early-stage discovery services and biotech customer base, with growing proteomics/biomarker overlap.
Market position
Strengths5 records
Weaknesses2 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
RxCelerate social profiles
Digital presenceRxCelerate financial estimates
Financial estimateRevenue estimate
Valuation estimate
RxCelerate leadership team
Management profileNumber of profiles
Profiles2 records
RxCelerate funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
RxCelerate M&A and investment
M&A and investmentM&A3 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about RxCelerate
What does RxCelerate do?
RxCelerate delivers complete preclinical drug development programmes and project management for virtual and semi-virtual biotechnology and pharmaceutical companies. Its offering is anchored by the proprietary ProQuant™ proteomics platform, which provides high quantitative accuracy proteomics services enabling advanced applications in drug discovery and development, including biologic therapeutic candidates developed in partnership with programmable biology platforms.
Is RxCelerate a public or private company?
RxCelerate is a private company. It is classified as unknown and is currently operating.
When was RxCelerate founded?
RxCelerate was founded in 2012. It employs 51 to 100 people.
Where is RxCelerate based?
RxCelerate is headquartered in Babraham, United Kingdom, in the Europe region.
Who are RxCelerate's main competitors?
Direct peers on record are Evotec, Sygnature Discovery, Domainex, Concept Life Sciences and Selvita. Broad incumbents are Charles River Laboratories, Pharmaron, WuXi AppTec and Eurofins Discovery. Crown Bioscience is listed as an emerging player.
Does RxCelerate have an API?
No public API is recorded for RxCelerate.
What industry is RxCelerate in?
RxCelerate's product category is Preclinical Drug Development Services. Its primary akta.pro industry code is HLAGADAG, Proteomics & Biomarker Analytical Testing, with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 8071.